Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study
Antithrombin, protein C and S defects are well-recognized inherited risk factors for venous thromboembolism (VTE). Although these defects have been reported to increase the risk of VTE in fertile women under combined oral contraceptives (COCs), the magnitude of this association is uncertain. In a s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-11-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://btvb.org/btvb/article/view/42 |
| _version_ | 1797835191077568512 |
|---|---|
| author | Daniela Tormene Elena Campello Chiara Simion Anna Poretto Paolo Prandoni Paolo Simioni |
| author_facet | Daniela Tormene Elena Campello Chiara Simion Anna Poretto Paolo Prandoni Paolo Simioni |
| author_sort | Daniela Tormene |
| collection | DOAJ |
| description |
Antithrombin, protein C and S defects are well-recognized inherited risk factors for venous thromboembolism (VTE). Although these defects have been reported to increase the risk of VTE in fertile women under combined oral contraceptives (COCs), the magnitude of this association is uncertain. In a sub-analysis of a prospective cohort study, we evaluated the incidence of VTE occurring during treatment with COCs in fertile women who were family members of a proband with an objectively diagnosed VTE event and a documented defect of antithrombin, protein C or S. Of the 197 women of child-bearing age from 88 families who qualified for this analysis in a 17-year period, 112 (57%) were carriers of an inherited defect (23 antithrombin, 41 protein C and 48 protein S), whereas the remaining 85 were free from these abnormalities. Estrogen-progestin therapy was used by 19 of the 112 (17%) carriers of inherited thrombophilia for an overall period of 276 months, and by 17 of the 85 (20%) non-carriers for an overall period of 992 months. VTE events developed in 12 of the 19 (63%) carriers, leading to a monthly event rate of 4.3% (95% CI: 2.2 to 7.6), and in 2 of the 17 (12%) non-carriers, leading to a monthly rate of 0.2% (95% CI: 0.02 to 0.7), for a relative risk of 21 (95% CI, 4.7 to 92). Among family members of probands with inherited defects of antithrombin, protein C or S defects, the use of estrogen-progestin therapy in carriers of these abnormalities results in a risk of VTE events that is more than 20 times as high as that expected in non-carriers. Accordingly, the systematic screening for thrombophilia in these families has the potential to identify those subjects in whom this kind of hormonal treatment should be strongly discouraged.
|
| first_indexed | 2024-04-09T14:49:14Z |
| format | Article |
| id | doaj.art-c146392dca0e4bb48d5c9ad85ee77d26 |
| institution | Directory Open Access Journal |
| issn | 2785-5309 |
| language | English |
| last_indexed | 2024-04-09T14:49:14Z |
| publishDate | 2022-11-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Bleeding, Thrombosis and Vascular Biology |
| spelling | doaj.art-c146392dca0e4bb48d5c9ad85ee77d262023-05-02T10:09:32ZengPAGEPress PublicationsBleeding, Thrombosis and Vascular Biology2785-53092022-11-011310.4081/btvb.2022.42Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort studyDaniela Tormene0Elena Campello1Chiara Simion2Anna Poretto3Paolo Prandoni4Paolo Simioni5Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, PaduaThrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, PaduaThrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, PaduaThrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, PaduaArianna Foundation on Anticoagulation, BolognaThrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, Padua Antithrombin, protein C and S defects are well-recognized inherited risk factors for venous thromboembolism (VTE). Although these defects have been reported to increase the risk of VTE in fertile women under combined oral contraceptives (COCs), the magnitude of this association is uncertain. In a sub-analysis of a prospective cohort study, we evaluated the incidence of VTE occurring during treatment with COCs in fertile women who were family members of a proband with an objectively diagnosed VTE event and a documented defect of antithrombin, protein C or S. Of the 197 women of child-bearing age from 88 families who qualified for this analysis in a 17-year period, 112 (57%) were carriers of an inherited defect (23 antithrombin, 41 protein C and 48 protein S), whereas the remaining 85 were free from these abnormalities. Estrogen-progestin therapy was used by 19 of the 112 (17%) carriers of inherited thrombophilia for an overall period of 276 months, and by 17 of the 85 (20%) non-carriers for an overall period of 992 months. VTE events developed in 12 of the 19 (63%) carriers, leading to a monthly event rate of 4.3% (95% CI: 2.2 to 7.6), and in 2 of the 17 (12%) non-carriers, leading to a monthly rate of 0.2% (95% CI: 0.02 to 0.7), for a relative risk of 21 (95% CI, 4.7 to 92). Among family members of probands with inherited defects of antithrombin, protein C or S defects, the use of estrogen-progestin therapy in carriers of these abnormalities results in a risk of VTE events that is more than 20 times as high as that expected in non-carriers. Accordingly, the systematic screening for thrombophilia in these families has the potential to identify those subjects in whom this kind of hormonal treatment should be strongly discouraged. https://btvb.org/btvb/article/view/42Major thrombophiliaCombined oral contraceptivesvenous thromboembolismProspective cohort studyWomen's health |
| spellingShingle | Daniela Tormene Elena Campello Chiara Simion Anna Poretto Paolo Prandoni Paolo Simioni Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study Bleeding, Thrombosis and Vascular Biology Major thrombophilia Combined oral contraceptives venous thromboembolism Prospective cohort study Women's health |
| title | Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study |
| title_full | Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study |
| title_fullStr | Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study |
| title_full_unstemmed | Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study |
| title_short | Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study |
| title_sort | combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin protein c or s deficiency sub analysis of a prospective cohort study |
| topic | Major thrombophilia Combined oral contraceptives venous thromboembolism Prospective cohort study Women's health |
| url | https://btvb.org/btvb/article/view/42 |
| work_keys_str_mv | AT danielatormene combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy AT elenacampello combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy AT chiarasimion combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy AT annaporetto combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy AT paoloprandoni combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy AT paolosimioni combinedoralcontraceptivesandtheriskofvenousthromboembolismcarriersofantithrombinproteincorsdeficiencysubanalysisofaprospectivecohortstudy |